Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Recently, the board of directors at Gilead Sciences Inc. (GILD - Analyst Report) authorized a two-for-one stock split. The action, which will take shape through a stock dividend for stockholders as on record on January 7, 2013, is aimed at increasing  the number of authorized shares at Gilead to about 1.52 billion from 759.3 million (as of November 30). The stock dividend is expected to be distributed to the relevant stockholders on or about January 25, 2013.

Following the stock split, every shareholder at Gilead (on record on January 7, 2013) will get an additional share for each share he/she currently holds. Gilead intends to commence trading at the NASDAQ at the post-split price from January 28, 2013. Gilead in its press release further stated that purchasers of its shares between January 7 and January 28, 2013 will get a due-bill. The due bill will make the buyer eligible for an additional share for each share bought.

We note that shares of Gilead Sciences have been on an uptrend since the beginning of the year driven by multiple positive catalysts, including the purchase of Pharmasset, targeting the lucrative hepatitis C virus (HCV) market and the approval of the high potential HIV therapy, Stribild. The stock is currently hovering around its 52-week high of $76.28, reached on November 23, 2012. We believe that the soaring stock price necessitated the 2-for-1 stock split.

Apart from the positive developments noted above, Gilead received further good news last month when it presented encouraging top-line data on its HCV candidate sofosbuvir from a phase III study. Sofosbuvir (formerly GS-7977) was added to Gilead’s pipeline through its acquisition of Pharmasset in January 2012.

Apart from Gilead, companies such as Abbott Laboratories (ABT - Analyst Report), Johnson & Johnson (JNJ - Analyst Report) and Bristol-Myers Squibb (BMY - Analyst Report) are also developing therapies to combat HCV.

Our Recommendation

We currently have a Neutral recommendation on Gilead. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +6.05%
QUESTCOR PHA QCOR 80.07 +2.47%
VIPSHOP HOLD VIPS 156.35 +1.82%
ENLINK MIDST ENLC 36.29 +1.60%
BNC BANCORP BNCN 17.33 +1.58%